Pharmaceuticals

This channel includes news and new technology innovations for cardiovascular pharmaceutics. This includes antiplatelet agents, anticoagulation drugs, INR testing, NOAC, OAC, IV administered drugs such as Heprin, and dual antiplatelet therapy.

News | Antiplatelet and Anticoagulation Therapies

November 3, 2017 β€” A ten-year decline in the blood cholesterol of heart attack patients in Malaysia suggests statins are ...

Home November 03, 2017
Home
News | Stents Drug Eluting

November 1, 2017 β€” OrbusNeich reported results from the REDUCE trial in the Late-Breaking Clinical Trial session at the ...

Home November 01, 2017
Home
News | Stents

October 27, 2017 β€” CeloNova BioSciences Inc. announced the U.S. Food and Drug Administration (FDA) approved expansion of ...

Home October 27, 2017
Home
News | Stem Cell Therapies

October 24, 2017 β€” Roche and Ncardia have reached a broad licensing agreement whereby Roche and its affiliate companies ...

Home October 24, 2017
Home
News | Pharmaceuticals

October 18, 2017 β€” Results from the pivotal Phase 3 COMPASS study found that the Xarelto vascular dose plus aspirin 100 ...

Home October 18, 2017
Home
News | Pharmaceuticals

October 4, 2017 β€” MyoKardia Inc. recently provided a clinical update on its MYK-491 program for dilated cardiomyopathy.

...

Home October 04, 2017
Home
News | Heart Failure

September 19, 2017 β€” The heart failure space across the seven key markets of the U.S., France, Germany, Italy, Spain ...

Home September 19, 2017
Home
News | Pharmaceuticals

September 12, 2017 β€” Inclisiran lowers low-density lipoprotein (LDL, or β€œbad”) cholesterol for up to one year in ...

Home September 12, 2017
Home
News | ESC

September 12, 2017 β€” Very aggressive reduction of LDL-cholesterol to ultra-low levels was associated with progressively ...

Home September 12, 2017
Home
News | ESC

September 12, 2017 β€” The IL-1Ξ² inhibitor canakinumab lowers the risk of cardiovascular disease and lung cancer risk by ...

Home September 12, 2017
Home
COMPASS Trial Shows Rivaroxaban With Aspirin Improves Stable Cardiovascular Disease
Feature | Antiplatelet and Anticoagulation Therapies

September 12, 2017 β€” Rivaroxaban plus aspirin improves survival and reduces stroke and heart attack in patients with ...

Home September 12, 2017
Home
News | Pharmaceuticals

September 11, 2017 β€” Merck and researchers in the Clinical Trial Service Unit at the University of Oxford announced the ...

Home September 11, 2017
Home
News | Atrial Fibrillation

September 1, 2017 β€” Apixaban lowers the risk of stroke compared to warfarin in anticoagulation-naΓ―ve patients with ...

Home September 01, 2017
Home
News | Antiplatelet and Anticoagulation Therapies

August 28, 2017 β€” Bristol-Myers Squibb Company and Pfizer Inc. announced results from an analysis of real-world data ...

Home August 28, 2017
Home
News | Antiplatelet and Anticoagulation Therapies

August 18, 2017 β€” Medtronic plc announced a global randomized clinical trial that will evaluate one-month dual ...

Home August 18, 2017
Home
Subscribe Now